Suzhou Ribo Life Science Co., Ltd.

Suzhou Ribo Life Science Co., Ltd. is a biopharmaceutical company dedicated to advancing innovative RNA interference (RNAi) technologies and oligonucleotide therapeutics. Established in 2007, the company's mission is to address unmet clinical needs globally and improve human health. Headquartered in Kunshan, Jiangsu Province, China, Ribo also maintains R&D centers in Beijing, China, and Gothenburg, Sweden, reflecting its global strategic footprint.

The company specializes in the development of small interfering RNA (siRNA) drugs, focusing on therapeutic areas such as cardiovascular, metabolic, renal, and liver diseases, including rare diseases. Key pipeline assets in clinical development include RBD4059 for thrombotic diseases, RBD5044 for hypertriglyceridemia, RBD7022 for hyperlipidemia, RBD7007 and RBD2080 for renal diseases, RBD1119 for thrombotic diseases, and RBD1016 for chronic hepatitis B. Ribo leverages its proprietary RiboGalSTAR™ liver-targeting delivery platform to enhance the precision and efficacy of its oligonucleotide drugs.

Suzhou Ribo Life Science Co., Ltd. successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEX: 06938) in January 2026, marking a significant milestone for the company. Dr. Liang Zicai serves as the founding Chairman and CEO, leading the company's strategic direction. Dr. Hongyan Zhang is the President, and Dr. Liming Gan is Co-CEO and President of Global Product R&D. In March 2026, Dr. Anders Gabrielsen was appointed Chief Medical Officer and Dr. John Taylor as Chief Business Officer. Ribo is recognized as a pioneer and leader in RNAi technology and oligonucleotide drug development in China, actively pursuing collaborations with global pharmaceutical companies such as Madrigal and Boehringer Ingelheim to advance its pipeline and expand its market reach.